Pfizer has considered manufacturing shifts in the United States amid the looming tariff threat. Analysts – Merck (NYSE: MRK), Eli Lilly (NYSE: LLY) Asked: “The Trump administration will invest together”

In view of the president’s potential tariff threat Donald Trump,,,,, Pfizers PFE CEO Albert Bourla The possibility of transferring the company’s overseas manufacturing industry to its US facilities has been proposed.

what happened: At the TD Cowen Healthcare conference, Bourla said Pfizer already has an extensive U.S. manufacturing network that can transfer production to its domestic factories to avoid any potential tariffs.

His comments are because the pharmaceutical industry may have a tariff of 25% on imported goods. “We have features here (in the US) and the manufacturing site is currently running well. If something happens, we will try to mitigate it by moving from the manufacturing site outside to the manufacturing site here,” Bourla said.

Pfizer has 10 manufacturing facilities and two distribution centers in the United States.

See: Trump’s tariffs threaten Canadian, Mexico, China and U.S. wallets

Why it matters: This development came in February from Trump to warn pharmaceutical companies. At a confidential meeting, the president urged pharmaceutical companies to speed up the transfer of their overseas production to the United States, or face the possibility of tariffs.

Among the participants in this meeting were Eli Lilly & Co. Lai,,,,, Merck. MRKand heads of Pfizer, and the industry’s largest lobby group. Executives aim to convince Trump to support measures against middlemen, accusing raising out-of-pocket expenses and limiting laws that allow the federal government to negotiate specific drug prices.

Although the Trump administration has suggested that reciprocity tariffs may be exempted in certain sectors, including drugs, no final decision has been made.

although Many people think that redesign is a potential solution to avoid tariffs, which may not be pragmatic. Independent Medical Analyst Joshua P. Cohen “It takes time and is logistically complicated,” writes Forbes. He said that general products may require a purchase of bulk purchase guarantees, And public-private partnerships may be required to improve infrastructure and regulatory compliance. “It remains to be seen whether the Trump administration is ready to invest in a long-term strategy,” Cohen said.

Image via shutterstock

Disclaimer: The content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.